Currently, there are 662.48M common shares owned by the public and among those 126.80M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of 15.07% and -17.65% over the past three months. OLPX shares are trading -2.89% year to date (YTD), with the 12-month market performance down to -9.68% lower. It has a 12-month low price of $1.19 and touched a high of $2.77 over the same period. OLPX has an average intraday trading volume of 1.38 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 14.79%, 6.94%, and -9.56% respectively.
Institutional ownership of Olaplex Holdings Inc (NASDAQ: OLPX) shares accounts for 19.89% of the company’s 662.48M shares outstanding.
It has a market capitalization of $1.11B and a beta (3y monthly) value of 2.42. The stock’s trailing 12-month PE ratio is 26.37, while the earnings-per-share (ttm) stands at $0.06. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.87% over the week and 5.28% over the month.
Earnings per share for the fiscal year are expected to decrease by -16.24%, and -0.75% over the next financial year. EPS should shrink at an annualized rate of -10.07% over the next five years, compared to -0.81% over the past 5-year period.
Looking at the support for the OLPX, a number of firms have released research notes about the stock. Telsey Advisory Group stated their Market Perform rating for the stock in a research note on August 07, 2024, with the firm’s price target at $2-$3. Piper Sandler coverage for the Olaplex Holdings Inc (OLPX) stock in a research note released on March 19, 2024 offered a Neutral rating with a price target of $2. Barclays was of a view on October 04, 2023 that the stock is Equal Weight, while Piper Sandler gave the stock Underweight rating on August 25, 2023, issuing a price target of $3- $2. Canaccord Genuity on their part issued Hold rating on August 11, 2023.
